Altuviiio May See Rapid Uptake Upon European Approval In Hemophilia A
Pediatric Data Clears Path For EMA Filing
Executive Summary
Sanofi announced results from its XTEND-Kids trial, clearing the last requirement before an anticipated second half filing for Altuviiio’s approval with the EMA.
You may also be interested in...
Sanofi’s Altuviiio Set To Reenergize Factor VIII Space
The once-weekly Factor VIII replacement therapy for hemophilia A, newly approved by the US FDA, appears well positioned to compete with Roche’s blockbuster Hemlibra.
Sanofi Looks To Dominate $5bn Hemophilia A Factor Market After Trial Success
Phase III success for efanesoctocog alfa sets up a filing in the near future, and a chance to seize market share from existing Factor VIII products, as well as Roche’s Hemlibra.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.